Rate of CKD Diagnosis in Patients With AH and CKD MarkersD1843R00359NCT06744335
Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)
An observational study of Rate of CKD Diagnosis in Patients With AH and CKD Markers and Demographic and Clinical Characteristics for Those Patients, run by AstraZeneca at 28 sites in Kazakhstan.
Trial summary
Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients, Routine Therapy Before and After the Diagnosis of CKD
- How many people
- 1,283 participants
- Where
- 28 sitesKazakhstan
- Study dates
- 20 Jan 2025to 20 Aug 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The planned study population for the prospective analysis consists of 1,282 adult outpatients with AH with one or more markers of CKD, without a documented diagnosis of CKD before inclusion in the study and without a documented diagnosis of DM or III-IV stage chronic heart failure (CHF). The planned number of study centers is ~15 outpatient sites in approximately 10 regions of Kazakhstan. The retrospective part includes a physician's retrospective review of the ambulatory cards or medical records of outpatients with a reported diagnosis of arterial hypertension for the presence of laboratory markers of CKD assessed ≥3 and ≤12 months prior to inclusion.
Who may be able to join
- Age ≥18 years at the time of inclusion;
- Patient signed and dated written informed consent form (ICF) in accordance with ICH GCP and local legislation prior to inclusion in the study for the prospective observational cohort;
- Established diagnosis of hypertension, diagnosed in accordance with current clinical guidelines for hypertension, i.e. in adults, i.e. systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg. when measured at two different visits
- Laboratory markers of CKD (eGFR <60 mL/min/1.73 m2 and/or albuminuria/proteinuria*) measured during the period ≤12 months prior to inclusion in the study and persisting ≥3 months between two measurements without a recorded diagnosis of CKD in the primary medical record prior to inclusion;
- any of the following: urine albumin/creatinine ratio (UACR) ≥30 mg/g (3 mg/mmol), Urine protein-creatinine ratio (uPCR) ≥150 mg/g (15 mg/mmol), albuminuria ≥30 mg/d or Urine protein-creatinine ratio (uPCR) ≥0.15 mg/d.
- Absence of documented diagnosis of CKD in the patient's medical records prior to inclusion in the study
Who cannot join
- Absence of a signed ICF in patients in the prospective follow-up group
- Participation in any randomized controlled trial within 3 months prior to inclusion in this study or during participation in this study
- An established diagnosis of type 1 or type 2 diabetes mellitus.
- Diagnosis of symptomatic chronic heart failure (CHF), NYHA functional class III-IV, documented in the patient's medical records
- Diagnosis of AH of secondary genesis
Trial locations and contacts
28 sites in 1 country.
28 sites in 1 country
Kazakhstan28 sites
City Polyclinic No. 4
Aktobe
City Cardiology Center
Almaty
Interna Clinic, Scientific Centre for Internal Medicine LLP
Almaty
JSC Research Institute of Cardiology and Internal Diseases
Almaty
LLP Almaty Sema Hospital
Almaty
Municipal state enterprise with the right of economic management City polyclinic No. 5
Almaty
National Hospital of Medical Center of the Presidents Affairs Administration of the Republic of Kazakhstan
Almaty
AIS Clinic
Astana
City Polyclinic No. 2
Astana
Family Health Center Shipager
Astana
Green Clinic
Astana
Medical Center Hospital of the President's Affairs Administration of the Republic of Kazakhstan
Astana
Medical Center Zhanuya
Astana
Onege Family Health and Happiness Centre, LLP
Astana
State Enterprise on the Right of Economic Management City Polyclinic No. 5 Astana
Astana
State Enterprise on the Right of Economic Management City Polyclinic No. 6 Astana
Astana
UMC Diagnostic Centre
Astana
Enbekshikazakh Multidisciplinary Interdistrict Hospital
Esik
City Polyclinic No. 1
Karaganda
City Polyclinic No. 3
Karaganda
Communal State Enterprise Polyclinic No. 4 of Kostanay City
Kostanay
Communal State Enterprise on the right of economic management City Polyclinic No. 7
Semey
LLP Sau Zhurek Healthy Heart
Shymkent
NJSC Heart Centre Shymkent
Shymkent
IE Dr.Selina
Stepnogorsk
Ordabasy Central District Hospital
Temirlanovka, Turkistan Oblast
Clinical and Diagnostic Center of the International Kazakh-Turkish University named after Khoja Ahmet Yasawi
Turkestan
State Enterprise on the Right of Economic Management Zhambyl District Central Hospital
Uzynaghash
About this study
Official title: Prospective Observational Multicenter Study of Patients With Arterial Hypertension and Chronic Kidney Disease Markers in Kazakhstan (PROGRESS-CKD)
Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan
Read the detailed description
Primary endpoints:
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).
Secondary endpoints:
The following secondary endpoints will be evaluated in all patients with AH and markers of CKD included in the study (Full Analysis Sampling - FAS) (Secondary Aim 1) and in the subgroup of patients with a diagnosis of CKD confirmed during the study (Modified Full Analysis Sampling - mFAS), i.e., at Visit 1 or
Visit 2 (Secondary Aim 2):
What is being measured
The primary outcome is the main question the study is designed to answer.
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).
Measured: 16 months
Secondary outcomes (5)
1. Frequency of microalbuminuria, proteinuria, reduced glomerular filtration rate (GFR <60 ml/min/1.73 m²) and other markers of kidney damage in patients with arterial hypertension.
- Frequency of microalbuminuria, proteinuria, reduced glomerular filtration rate (GFR <60 ml/min/1.73 m²) and other markers of kidney damage in patients with arterial hypertension.
Measured: 16 months
2. Proportion of patients with various risk factors (age, gender, BMI, bad habits, blood pressure, cardiovascular risks) for the development and progression of CKD in patients with arterial hypertension.
- Proportion of patients with various risk factors (age, gender, BMI, bad habits, blood pressure, cardiovascular risks) for the development and progression of CKD in patients with arterial hypertension.
Measured: 16 months
3.Proportion of patients with various clinical characteristics, such as: • Average and median duration of AH years • Patients with different stages of AH and categories of cardiovascular risk.• Patients with uncontrolled and resistant hypertension.
- Proportion of patients with various clinical characteristics, such as:
- Average and median duration of hypertension, years (from the diagnosis date to Visit 1);
- Patients with different stages of hypertension (I, II, III) and categories of cardiovascular risk (low, moderate, high, very high).
- Patients with uncontrolled and resistant hypertension.
Measured: 16 months
4. The proportion of patients taking the following groups of drugs for the treatment of AH before inclusion in the study and during participation in the study: • ACE • Alfa or Beta-blockers; • ARBs •CCB • Diuretics • ARNI• Centrally acting drugs; • MRA.
- The proportion of patients taking the following groups of drugs for the treatment of hypertension before inclusion in the study and during participation in the study:
- ACE (angiotensin-converting enzyme) inhibitors;
- Beta-blockers;
- ARBs (angiotensin receptor blockers);
- Calcium channel blockers (CCB);
- Diuretics (thiazide, thiazide-like, loop);
- Angiotensin receptor-neprilysin inhibitor (ARNI);
- Alpha-blockers;
- Centrally acting drugs;
- Mineralocorticoid receptor antagonists (MRA).
Measured: 16 months
5. Proportion of patients with: • concomitant CVD and complications of AF/AFL, ventricular arrhythmias; CHD; MI; cerebrovascular diseases; stroke, TIA; • other concomitant diseases (in general and for each disease).
- Proportion of patients with:
- concomitant cardiovascular diseases (CVD) and complications of hypertension (atrial fibrillation/atrial flutter (AF/AFL), ventricular arrhythmias; coronary heart disease (CHD); myocardial infarction (MI); cerebrovascular diseases; stroke, transient ischemic attack (TIA);
- other concomitant diseases (in general and for each disease).
Measured: 16 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Dec 2024
- Study start20 Jan 2025
- Primary completion20 Aug 2026
- Study completion20 Aug 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rate of CKD Diagnosis in Patients With AH and CKD MarkersStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 1,283 participants (actual)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06744335
- Sponsor's protocol ID
- D1843R00359
- Acronym
- D1843R00359
- Status last verified
- Aug 2026
- First submitted
- 17 Dec 2024
- Last updated
- 31 Aug 2026
- Results posted
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Study at a glance
From the registry record, last updated by the sponsor on 31 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Observational Multicenter Study of Patients With Arterial Hypertension and Chronic Kidney Disease Markers in Kazakhstan (PROGRESS-CKD)
- ClinicalTrials.gov ID
- NCT06744335
- Acronym / sponsor ID
- D1843R00359 / D1843R00359
- Conditions
- Rate of CKD Diagnosis in Patients With AH and CKD Markers, Demographic and Clinical Characteristics for Those Patients, Routine Therapy Before and After the Diagnosis of CKD
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1,283 participants (actual)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 20 Jan 2025 (actual)
- Primary completion
- 20 Aug 2026 (actual)
- Study completion
- 20 Aug 2026 (actual)
- First posted
- 20 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multicenter, non-interventional PRospective Observational study with retrospective analysis to describe the rate of CKD diaGnosis in patients with aRtErial hypErtenSion and CKD markerS in Kazakhstan
Detailed description
Primary endpoints:
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).
Secondary endpoints:
The following secondary endpoints will be evaluated in all patients with AH and markers of CKD included in the study (Full Analysis Sampling - FAS) (Secondary Aim 1) and in the subgroup of patients with a diagnosis of CKD confirmed during the study (Modified Full Analysis Sampling - mFAS), i.e., at Visit 1 or
Visit 2 (Secondary Aim 2):
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The planned study population for the prospective analysis consists of 1,282 adult outpatients with AH with one or more markers of CKD, without a documented diagnosis of CKD before inclusion in the study and without a documented diagnosis of DM or III-IV stage chronic heart failure (CHF). The planned number of study centers is ~15 outpatient sites in approximately 10 regions of Kazakhstan. The retrospective part includes a physician's retrospective review of the ambulatory cards or medical records of outpatients with a reported diagnosis of arterial hypertension for the presence of laboratory markers of CKD assessed ≥3 and ≤12 months prior to inclusion.
Key inclusion criteria (6 listed)
- Age ≥18 years at the time of inclusion;
- Patient signed and dated written informed consent form (ICF) in accordance with ICH GCP and local legislation prior to inclusion in the study for the prospective observational cohort;
- Established diagnosis of hypertension, diagnosed in accordance with current clinical guidelines for hypertension, i.e. in adults, i.e. systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg. when measured at two different visits
- Laboratory markers of CKD (eGFR <60 mL/min/1.73 m2 and/or albuminuria/proteinuria*) measured during the period ≤12 months prior to inclusion in the study and persisting ≥3 months between two measurements without a recorded diagnosis of CKD in the primary medical record prior to inclusion;
- Absence of documented diagnosis of CKD in the patient's medical records prior to inclusion in the study
Key exclusion criteria (5 listed)
- Absence of a signed ICF in patients in the prospective follow-up group
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).
Time frame: 16 months
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5).
5 secondary outcomes
1. Frequency of microalbuminuria, proteinuria, reduced glomerular filtration rate (GFR <60 ml/min/1.73 m²) and other markers of kidney damage in patients with arterial hypertension.
Time frame: 16 months
2. Proportion of patients with various risk factors (age, gender, BMI, bad habits, blood pressure, cardiovascular risks) for the development and progression of CKD in patients with arterial hypertension.
Time frame: 16 months
3.Proportion of patients with various clinical characteristics, such as: • Average and median duration of AH years • Patients with different stages of AH and categories of cardiovascular risk.• Patients with uncontrolled and resistant hypertension.
Time frame: 16 months
4. The proportion of patients taking the following groups of drugs for the treatment of AH before inclusion in the study and during participation in the study: • ACE • Alfa or Beta-blockers; • ARBs •CCB • Diuretics • ARNI• Centrally acting drugs; • MRA.
Time frame: 16 months
5. Proportion of patients with: • concomitant CVD and complications of AF/AFL, ventricular arrhythmias; CHD; MI; cerebrovascular diseases; stroke, TIA; • other concomitant diseases (in general and for each disease).
Time frame: 16 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 Aug 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
28 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Rate of CKD Diagnosis in Patients With AH and CKD Markers and Demographic and Clinical Characteristics for Those Patients, run by AstraZeneca at 28 sites in Kazakhstan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 31 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 28 sites in Kazakhstan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The proportion of patients with markers of chronic kidney disease (CKD) among patients with arterial hypertension such as: albuminuria/proteinuria; GFR <60 ml/min/1.73 m2 (CFR categories C3a-C5). (time frame: 16 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2026.